With respect to blood disorders, PD-1 or PD-L1 inhibitors greatly reduced the risk of anemia (RR: 0.50, 95% CI: 0.35–0.71) and neutrophil decrease (RR: 0.09, 95% CI: 0.06–0.16). Here, RPL17 is linked to anemia.